📣 VC round data is live. Check it out!

PhotoCure Valuation Multiples

Discover revenue and EBITDA valuation multiples for PhotoCure and similar public comparables like OnKure Therapeutics, Galectin Therapeutics, Milestone Pharmaceuticals, Hyloris Pharmaceuticals and more.

PhotoCure Overview

About PhotoCure

PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products and specialty pharmaceutical companies. The technology platform of the company is focused on the field of photodynamic diagnosis and treatment of cancer. The company has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, BeNeLux, Italy, Other European countries, Canada, and the United States.


Founded

1997

HQ

Norway

Employees

101

Financials (LTM)

Revenue: $63M
EBITDA: $7M

EV

$148M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

PhotoCure Financials

PhotoCure reported last 12-month revenue of $63M and EBITDA of $7M.

In the same LTM period, PhotoCure generated $58M in gross profit, $7M in EBITDA, and $4M in net income.

Revenue (LTM)


PhotoCure P&L

In the most recent fiscal year, PhotoCure reported revenue of $58M and EBITDA of $6M.

PhotoCure is unprofitable as of last fiscal year, with gross margin of 92%, EBITDA margin of 10%, and net margin of (0%).

See analyst estimates for PhotoCure
LTMLast FY202320242025202620272028
Revenue$63M$58M$54M$57M$58M
Gross Profit$58M$53M$51M$54M$53M
Gross Margin93%92%95%94%92%
EBITDA$7M$6M$7M$7M$4M
EBITDA Margin12%10%13%12%7%
EBIT Margin4%(0%)6%4%(0%)
Net Profit$4M($160K)$106K($362K)($164K)
Net Margin7%(0%)0%(1%)(0%)

Financial data powered by Morningstar, Inc.

PhotoCure Stock Performance

PhotoCure has current market cap of $173M, and enterprise value of $148M.

Market Cap Evolution


PhotoCure's stock price is $6.48.

PhotoCure share price decreased by 3.3% in the last 30 days, and increased by 14.8% in the last year.

PhotoCure has an EPS (earnings per share) of $-0.01.

See more trading valuation data for PhotoCure
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$148M$173M-3.3%-3.3%2.5%14.8%$-0.01

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

PhotoCure Valuation Multiples

PhotoCure trades at 2.4x EV/Revenue multiple, and 19.8x EV/EBITDA.

See NTM and 2027E valuation multiples for PhotoCure

EV / Revenue (LTM)


PhotoCure Financial Valuation Multiples

As of June 2, 2026, PhotoCure has market cap of $173M and EV of $148M.

PhotoCure has a P/E ratio of 40.2x.

LTMLast FY202320242025202620272028
EV/Revenue2.4x2.6x2.7x2.6x2.6x
EV/EBITDA19.8x25.2x21.5x21.0x36.6x
EV/EBIT56.4xn/m49.2x67.1xn/m
EV/Gross Profit2.5x2.8x2.9x2.8x2.8x
P/E40.2xn/mn/mn/mn/m
EV/FCF55.9x137.2x38.0x21.0x137.2x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified PhotoCure Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

PhotoCure Margins & Growth Rates

PhotoCure grew revenue by 24% and EBITDA by 65% in the last fiscal year.

In the most recent fiscal year, PhotoCure reported gross margin of 92%, EBITDA margin of 10%, and net margin of (0%).

See estimated margins and future growth rates for PhotoCure

PhotoCure Margins

Last FY202420252026202720282029
Gross Margin92%94%92%94%
EBITDA Margin10%12%7%14%
EBIT Margin(0%)4%(0%)9%
Net Margin(0%)(1%)(0%)15%
FCF Margin2%12%2%12%

PhotoCure Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth24%5%1%24%
Gross Profit Growth27%4%(1%)27%
EBITDA Growth65%2%(43%)139%
EBIT Growth(8071%)(27%)(104%)(8071%)
Net Profit Growth(6630%)(441%)(55%)(6464%)
FCF Growth675%81%(85%)675%

Data powered by FactSet, Inc. and Morningstar, Inc.

PhotoCure Operational KPIs

PhotoCure's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.5M for the same period.

PhotoCure's Rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

PhotoCure's Rule of X is 74% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for PhotoCure
LTMLast FY202320242025202620272028
Rule of 4027%38%---
Bessemer Rule of X50%74%---
Revenue per Employee-$0.6M---
Opex per Employee-$0.5M---
S&M Expenses to Revenue-68%67%68%68%
R&D Expenses to Revenue-0%0%1%0%
Opex to Revenue-92%89%90%92%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
OnKure Therapeutics-(91.4x)0.3x-
Galectin Therapeutics--(14.6x)(14.5x)
Milestone Pharmaceuticals29.5x11.8x(0.8x)-
Hyloris Pharmaceuticals13.1x8.0x(22.4x)(11.5x)
Innate Pharma15.7x7.7x(4.9x)5.4x
Journey Medical2.7x2.4x57.7x25.9x
MediWound8.3x7.1x(6.9x)(5.5x)
Tiziana Life Sciences--(9.6x)-

This data is available for Pro users. Sign up to see all PhotoCure competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About PhotoCure

When was PhotoCure founded?PhotoCure was founded in 1997.
Where is PhotoCure headquartered?PhotoCure is headquartered in Norway.
How many employees does PhotoCure have?As of today, PhotoCure has over 101 employees.
Who is the CEO of PhotoCure?PhotoCure's CEO is Daniel Schneider.
Is PhotoCure publicly listed?Yes, PhotoCure is a public company listed on Oslo Børs.
What is the stock symbol of PhotoCure?PhotoCure trades under PHO ticker.
When did PhotoCure go public?PhotoCure went public in 2000.
Who are competitors of PhotoCure?PhotoCure main competitors include OnKure Therapeutics, Galectin Therapeutics, Milestone Pharmaceuticals, Hyloris Pharmaceuticals, Innate Pharma, Journey Medical, MediWound, Tiziana Life Sciences, NRX Pharmaceuticals, Mycenax Biotech.
What is the current market cap of PhotoCure?PhotoCure's current market cap is $173M.
What is the current revenue of PhotoCure?PhotoCure's last 12 months revenue is $63M.
What is the current revenue growth of PhotoCure?PhotoCure revenue growth (NTM/LTM) is 15%.
What is the current EV/Revenue multiple of PhotoCure?Current revenue multiple of PhotoCure is 2.4x.
What is the current EBITDA of PhotoCure?PhotoCure's last 12 months EBITDA is $7M.
What is PhotoCure's EBITDA margin?PhotoCure's last 12 months EBITDA margin is 12%.
What is the current EV/EBITDA multiple of PhotoCure?Current EBITDA multiple of PhotoCure is 19.8x.
What is the current FCF of PhotoCure?PhotoCure's last 12 months FCF is $3M.
What is PhotoCure's FCF margin?PhotoCure's last 12 months FCF margin is 4%.
What is the current EV/FCF multiple of PhotoCure?Current FCF multiple of PhotoCure is 55.9x.
How many companies PhotoCure has acquired to date?PhotoCure hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies PhotoCure has invested to date?PhotoCure hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to PhotoCure

Lists including PhotoCure

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial